Freedom of information requests

Lung cancer treatment

Questions

1. How many non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:
2. How many patients were treated for Squamous non-small cell lung cancer (Sq NSCLC) ONLY in the past 3 months with:

Response

The Trust does hold all of the information you have requested, however we are withholding some of it for the following reasons:

Section 40 – Personal Information

Section 40 (2) of the Freedom of Information Act (2000) allows public authorities to withhold personal data where it is protected under the Data Protection Act.

“Personal data” means any information relating to an identified living individual.

We have therefore withheld the exact number of patients where this is 5 or less (replaced with the <6 symbol), as this could be potentially identifiable and as such is protected from disclosure by Section 40 (2) of the FOI Act.

1. Drug	No. of Patients
   ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib)	0
   Amivantamab	0
   Atezolizumab Monotherapy	0
   Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel	0
   Dabrafenib + Trametinib	0
   Docetaxel monotherapy or in combination with Carboplatin/Cisplatin	0
   Durvalumab	0
   Gemcitabine	0
   Nitedanib + Docetaxel	0
   Nivolumab	0
   Osimertinib	<6
   Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib)	<6
   Paclitaxel	0
   Pembrolizumab Monotherapy	<6
   Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin)	0
   Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin)
   Pemetrexed + Platinum (Carboplatin/Cisplatin)	0
   RET Inhibitors (Pralsetinib, Selpercatinib)	0
   Sotorasib	0
   Tepotinib	0
   Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin	<6
   Other active systemic anti-cancer therapy	0
   Palliative care only	0

   
   
   

2. Drug	No. of Patients
   Atezolizumab monotherapy	<6
   Durvalumab	0
   Gemcitabine	0
   Nivolumab	0
   Osimertinib	<6
   Pembrolizumab (Keytruda) Mono	<6
   Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin)	0
   Paclitaxel	<6
   Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin	<6
   Other active systemic anti-cancer therapy (SACT)	0
   Palliative care only	0